Vaxart Announces Adjournment of Special Meeting of Stockholders

Group 1 - Vaxart's special meeting of stockholders has been adjourned to September 19, 2025, to allow stockholders more time to consider proposals due to changes in Board composition and governance [1][2] - The reconvened meeting will be held virtually, and stockholders can access it using a control number provided in their proxy materials [3] - Stockholders who have not yet voted are encouraged to do so by September 18, 2025, and those who previously voted against the reverse stock split proposal can change their vote [5] Group 2 - Vaxart is a clinical-stage biotechnology company focused on developing oral recombinant vaccines that can be stored and shipped without refrigeration [6] - The company's vaccine development programs include candidates for coronavirus, norovirus, influenza, and a therapeutic vaccine for human papillomavirus (HPV) [6] - Vaxart has filed patent applications covering its proprietary technology for oral vaccination using adenovirus and TLR3 agonists [6]